Understanding how human antibodies can protect against tuberculosis

Characteristics and protective efficacy of human antibodies against M. tuberculosis

['FUNDING_R01'] · ALBERT EINSTEIN COLLEGE OF MEDICINE · NIH-10721412

This study is looking at how certain antibodies in our bodies can help protect against tuberculosis (TB) and aims to find out how a vaccine called BCG can improve these antibody responses, which could lead to better vaccines and treatments for people with TB.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorALBERT EINSTEIN COLLEGE OF MEDICINE (nih funded)
Locations1 site (BRONX, UNITED STATES)
Trial IDNIH-10721412 on ClinicalTrials.gov

What this research studies

This research investigates the role of human antibodies in providing protection against tuberculosis (TB), a serious infectious disease caused by Mycobacterium tuberculosis. The study aims to identify specific antibody responses that can be induced by vaccination, particularly focusing on the Bacillus Calmette-Guerin (BCG) vaccine, which has been used for nearly a century but offers limited protection. By characterizing the binding properties and functions of these antibodies, the research seeks to enhance our understanding of how they contribute to immunity against TB. Patients may benefit from insights that could lead to the development of more effective vaccines and therapies.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals who have been vaccinated with the BCG vaccine or those at risk of tuberculosis infection.

Not a fit: Patients who are not at risk for tuberculosis or those who have already developed active TB may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved vaccines and treatments for tuberculosis, potentially reducing its incidence and mortality.

How similar studies have performed: Other research has shown promise in understanding antibody responses in infectious diseases, suggesting that this approach could yield valuable insights into TB immunity.

Where this research is happening

BRONX, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.